BC
ABCL icon

Brookfield Corp’s AbCellera Biologics ABCL Stock Holding History

Brookfield Corp’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-50,000
Closed -$1.1M – 510
2021
Q2 		$1.1M Buy
+50,000
New +$1.38M 0.01% 439
2021
Q1 		– Sell
-45,754
Closed -$1.84M – 448
2020
Q4 		$1.84M Buy
+45,754
New +$2.09M 0.01% 299

Other funds holding ABCL

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $112B AUM 36.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
SM
SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return
GCAC
Guardian Capital Advisors (Canada) Toronto, Ontario, Canada $1.02B AUM 25.29% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Brookfield Corp's ABCL Position: Q3 2021 in Review

Brookfield Corp sold out of AbCellera Biologics (ABCL) in Q3 2021, closing a stake of 50,000 shares — an estimated $1.1M sold.

Brookfield Corp first reported a position in ABCL in Q4 2020 and held it in 2 quarters. The position peaked at $1.84M in Q4 2020. 116 funds tracked by Wall St. Rank hold ABCL as of Q3 2021.

  • Brookfield Corp reported no remaining AbCellera Biologics position as of Q3 2021 after selling out during the quarter.
  • Brookfield Corp sold 50,000 AbCellera Biologics shares in Q3 2021, an estimated $1.1M.
  • Brookfield Corp first reported a position in AbCellera Biologics in Q4 2020 and held it in 2 quarters.
  • Brookfield Corp's AbCellera Biologics position peaked at $1.84M in Q4 2020.
  • 116 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2021.

Based on Brookfield Corp's 13F filing for Q3 2021, filed 16 Nov 2021.